Ind-Swift Limited (INDSWFTLTD.BO)
- Previous Close
23.56 - Open
24.50 - Bid 24.73 x --
- Ask --
- Day's Range
24.50 - 24.73 - 52 Week Range
7.75 - 31.09 - Volume
41,183 - Avg. Volume
37,090 - Market Cap (intraday)
1.339B - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
4.49 - EPS (TTM)
5.51 - Earnings Date Feb 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 21, 2011
- 1y Target Est
--
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynaecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-allergic, neurology, and oncology. The company also provides Ayurvedic products, as well as contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries, as well as licenses its products to the United Kingdom, Europe, Canada, and Australia. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.
www.indswiftltd.com1,200
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: INDSWFTLTD.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDSWFTLTD.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDSWFTLTD.BO
Valuation Measures
Market Cap
1.28B
Enterprise Value
10.88B
Trailing P/E
4.28
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.28
Price/Book (mrq)
--
Enterprise Value/Revenue
2.36
Enterprise Value/EBITDA
9.16
Financial Highlights
Profitability and Income Statement
Profit Margin
6.30%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.73B
Net Income Avi to Common (ttm)
297.88M
Diluted EPS (ttm)
5.51
Balance Sheet and Cash Flow
Total Cash (mrq)
149.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: INDSWFTLTD.BO
INDSWFTLTD.BO does not have Company Insights